Results 161 to 170 of about 13,157 (218)

Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β₂-Agonist (ICS/LAMA/LABA) Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis. [PDF]

Adv Ther, 2020
Ferguson GT, Darken P, Ballal S, Siddiqui MK, Singh B, Attri S, Holmgren U, de Nigris E.   +7 more
europepmc   +1 more source

Glycopyrrolate/eFlow CS: The First Nebulized Long-Acting Muscarinic Antagonist Approved to Treat Chronic Obstructive Pulmonary Disease. [PDF]

Ann Pharmacother, 2019
Pleasants RA.
europepmc   +1 more source

Patient-Reported Burden of Illness in a Prevalent COPD Population Treated with Long-Acting Muscarinic Antagonist Monotherapy: A Claims-Linked Patient Survey Study. [PDF]

Pulm Ther, 2019
Hahn B, Stanford RH, Goolsby Hunter A, Essoi B, White J, Ray R.   +5 more
europepmc   +1 more source

Long-acting muscarinic antagonist and long-acting β2-agonist therapy to optimize chronic obstructive pulmonary disease prior to lung cancer surgery. [PDF]

Mol Clin Oncol, 2018
Makino T, Otsuka H, Hata Y, Koezuka S, Azuma Y, Isobe K, Sugino K, Ebihara S, Homma S, Iyoda A.   +9 more
europepmc   +1 more source

A new therapeutic choice for COPD: glycopyrronium bromide, a long-acting muscarinic antagonist

Folia Pharmacologica Japonica, 2013
Yoshisue, Hajime, Kozawa, Masanari, Hiratsuka, Maki, Nakanishi, Masaki   +3 more
openaire   +3 more sources

Systematic review and network meta-analysis of the efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler in comparison with other long-acting muscarinic antagonist/long-acting β₂-agonist fixed-dose combinations in COPD. [PDF]

Ther Adv Respir Dis, 2019
Siddiqui MK, Shukla P, Jenkins M, Ouwens M, Guranlioglu D, Darken P, Biswas M.   +6 more
europepmc   +1 more source

The risk factors of future exacerbations and treatment responses among different inhalation therapies of patients with preserved ratio impaired spirometry. [PDF]

J Glob Health
Cao J, Sun T, Yang H, Zhou L, Shen Q, Lin L, Li T, Zhang P, Zeng Y, Chen P, Song Q, Lei S, Li J.   +12 more
europepmc   +1 more source

Long-Acting Muscarinic Antagonists for the Treatment of Difficult-to-Treat and Severe Asthma: A Narrative Review Focusing on Inflammation from Bench to Bedside. [PDF]

J Inflamm Res
Calzetta L, Manzetti GM, Pistocchini E, Lauro RF, Gholamalishahi S, Cazzola M, Rogliani P.   +6 more
europepmc   +1 more source

Association Between Improvement in Institutional COPD Quality Assessment Grade and Risk of Acute Exacerbations in Primary and Secondary Care: A Nationwide Claims-Based Study. [PDF]

Int J Chron Obstruct Pulmon Dis
Moon SW, Lee H, Kim Y, Kim K, Rhee CK, Moon JY.   +5 more
europepmc   +1 more source

Appropriate Use of Single Inhaled Triple Therapy in Uncontrolled Asthma: A Multinational Modified Delphi Consensus. [PDF]

J Asthma Allergy
Mungan D, Cortes-Telles A, Mokhtar M, Daniel Colodenco F, Maillo M, Thomas PK, Mehta S, Al-Moamary MS, Tahoon H, Hussain R, Van Hasselt J, Hanania NA.   +11 more
europepmc   +1 more source